Changes in Hong Kong stocks | Yiming Onko-B (01541) rose another 10% IMM0306 treatment SLE latest data showed that SRI-4 response rate in week 24 reached a maximum of 90.9%

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Yiming Onko-B (01541) continued to rise. As of press release, it had risen 10% to HK$3.08, with a turnover of HK$1.776,600.

According to the news, Yiming Angke recently announced the latest results of the phase IB/II study of the CD47×CD20 bispecific fusion protein amurefurop α (IMM0306/IMC-002) in the treatment of moderately active SLE in the form of a poster at the 2026 annual meeting of the American Society of Rheumatology. This phase Ib data analysis included three dose groups of 0.8, 1.2, and 1.6 mg/kg, for a total of 33 patients. At week 24, SRI-4 response rates for the 0.8, 1.2, and 1.6 mg/kg dose groups were 71.4%, 72.7%, and 90.9%, respectively. At week 52, SRI-4 response rates were 66.7%, 75.0%, and 100%, respectively, showing long-lasting efficacy.